The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Spyre Therapeutics Inc shares valued at $1,049,778 were sold by Turtle Cameron on Nov 03 ’25. At $23.33 per share, Turtle Cameron sold 45,000 shares. The insider’s holdings dropped to 701,907 shares worth approximately $15.72 million following the completion of this transaction.
Also, CAMERON TURTLE purchased 90,000 shares, netting a total of over 2,201,400 in proceeds.
Before that, Burrows Scott L had sold 18,428 shares from its account. In a trade valued at $299,639, the Chief Financial Officer traded Spyre Therapeutics Inc shares for $16.26 each. Upon closing the transaction, the insider’s holdings decreased to 18,428 shares, worth approximately $2.19 million.
As published in their initiating research note from Deutsche Bank on September 26, 2025, Spyre Therapeutics Inc [SYRE] has been a Buy and the price target has been revised to $43. Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in early April. As of March 18, 2025, Wolfe Research has initiated its “an Outperform” rating for SYRE. Earlier on September 04, 2024, Wedbush initiated its rating. Their recommendation was “an Outperform” for SYRE stock.
Analyzing SYRE Stock Performance
On last trading session, Spyre Therapeutics Inc [NASDAQ: SYRE] plunged -2.01% to $22.39. The stock’s lowest price that day was $21.88, but it reached a high of $22.985 in the same session. During the last five days, there has been a drop of approximately -7.71%. Over the course of the year, Spyre Therapeutics Inc shares have dropped approximately -36.27%. Shares of the company reached a 52-week high of $26.01 on 01/07/25 and a 52-week low of $10.91 on 04/09/25.
Support And Resistance Levels for Spyre Therapeutics Inc (SYRE)
According to the 24-hour chart, there is a support level at 21.85, which, if violated, would cause prices to drop to 21.31. In the upper region, resistance lies at 22.96. The next price resistance is at 23.52. RSI (Relative Strength Index) is 54.68 on the 14-day chart, showing neutral technical sentiment.
Is Spyre Therapeutics Inc subject to short interest?
Stocks of Spyre Therapeutics Inc saw a sharp steep in short interest on 2025-10-15 dropping by -0.39 million shares to 13.39 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 13.78 million shares. A decline of -2.91% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 11.75 of the overall float, the days-to-cover ratio (short ratio) decline to 11.75.
Which companies own the most shares of Spyre Therapeutics Inc (SYRE)?
In terms of Spyre Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 43 in the next 12 months, up nearly 88.18% from the previous closing price of $22.85. Analysts anticipate Spyre Therapeutics Inc stock to reach 43 by 2025, with the lowest price target being 43. In spite of this, 3 analysts ranked Spyre Therapeutics Inc stock as Buy at the end of 2025.
